<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>5
<FILENAME>t1500018_ex10-5.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: Black"><B>Exhibit 10.5</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>CONFIDENTIAL TREATMENT REQUESTED
UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>[*] INDICATES OMITTED MATERIAL THAT
IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY
WITH THE COMMISSION.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">LICENSE AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #444642"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #444642"><FONT STYLE="color: Black">BETWEEN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #343431"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #343431"><FONT STYLE="color: Black">PROFESSOR DR. ERIC P. KRENNING</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #444642"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #444642"><FONT STYLE="color: Black">AND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black">BIOSYNTHEMA INC<FONT STYLE="font-size: 10pt">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>LICENSE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5pt"><FONT STYLE="color: Black">This
Agreement, executed this 12th day of June, 2007, (&quot;the Effective Date&quot;) is made by and between Professor Dr. Eric P. Krenning, Hoflaan 71, 3062 Je Rotterdam, The Netherlands (&quot;Krenning&quot;),
and <B>BioSynthema Inc., </B>a corporation organized under the laws of the State of Missouri, USA, and having its principal place
of business 4041 Forest Park Blvd., S1. Louis, Missouri, 63108 USA (&quot;BioSynthema&quot;), and hereafter referred to as the
&quot;Agreement&quot;. For the purpose of the Agreement, BioSynthema shall include a sublicensee to the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>INTRODUCTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">1.
WHEREAS, Krenning has made inventions relating to labelled somatostatin analogues covered in the patent case 100-7382 and patent case
118-7595, as set out in Schedule I annexed hereto (the &quot;Patent&quot;) as set out in Schedules I and Ia, which were assigned
to Novartis PharmaAG;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.05pt"><FONT STYLE="color: Black">2.
WHEREAS, Novartis Pharma AG of Basle, Switzerland, has entered into a License Agreement with Krenning signed on December 21, 2006 granting
Krenning a non-exclusive, royalty-bearing right to the Patent, with the right to sublicense (the &quot;Krenning License&quot;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.05pt"><FONT STYLE="color: Black">3.
WHEREAS, BioSynthema is the successor of certain intellectual property and related assets of Mallinckrodt Inc., to expand BioSynthema's
research, development and commercialization of radiopharmaceutical products in the field of oncology, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 34.1pt"><FONT STYLE="color: Black">4.
WHEREAS, Krenning is willing to grant to BioSynthema certain sublicense rights under the Krenning License, subject to the terms of the Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 34.55pt"><FONT STYLE="color: Black">NOW
THEREFORE, in consideration of the premises and the mutual covenants herein contained, the Parties mutually agree as follows:
-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="color: Black"><B>ARTICLE <FONT STYLE="font-size: 10pt">1.</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="color: Black"><B>DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">As used in the
Agreement, the following terms, whether used in the singular or plural, shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #3B3B38"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Affiliate</U>&quot;
an entity shall be deemed to be an &quot;Affiliate&quot; of BioSynthema whether a corporation or other business entity, that is
controlling, controlled by or under common control with BioSynthema.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Agreement</U>&quot;
means this agreement together with all exhibits, schedules, or appendices, as may be attached, all as respectively amended, modified
or supplemented by the Parties in accordance with the terms of the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>BioSynthema
License Rights</U>&quot; means the right to all of Krenning's interests in the Krenning License and as defined in Section 4.1.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>BioSynthema
Non-Exclusive Sublicense</U>&quot; means the non-exclusive sublicense granted by BioSynthema to a Third Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Commercialization</U>&quot;
means activities conducted by a Party either by itself or through a Third Party and directed to marketing, promoting, distributing,
importing, exporting, offering for sale or selling a Licensed Product, which may include pre-launch market preparation, whether
undertaken by a Party alone or with a partner or a sublicensee. When used as a verb, &quot;Commercialize&quot; means to engage
in Commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Control</U>&quot;
means the direct or indirect ownership of more than fifty percent (50%) of the equity interest in such corporation or business
entity, or the ability in fact to control the management decisions of such corporation or business entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Cover</U>&quot;
(including the variations such as &quot;Covered&quot;, &quot;Coverage&quot; or &quot;Covering&quot;) when applied to a patent
means that the making, using, offering for sale, selling or importing of a given product would infringe a Valid Claim of a patent
in the absence of a license under such patent. The determination of whether a product is Covered by a particular patent shall
be made on a country-by-country basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Diagnostic
Field</U>&quot; means the use of Licensed Product for diagnostic purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Dollars</U>&quot;
(including &quot;<U>U.S. Dollars</U>&quot; and the abbreviation &quot;<U>USD</U>&quot;) means the lawful currency of the United
States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Effective
Date</U>&quot; means the date set forth at the outset of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Euros</U>&quot; means the lawful currency of
the European Union.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Expiration
Date</U>&quot; means, in relation to Krenning's rights and obligations and BioSynthema's rights and obligations under the Agreement,
the date calculated on a country-by-country basis, upon which the Parties payment obligations shall expire.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>FDA</U>&quot; means thereto.
the United Stares Food and Drug Administration and any successor agency </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5pt"><FONT STYLE="color: Black">&quot;<U>First
Commercial Sales</U>&quot; means the first shipment of a Licensed Product to an independent Third Party, by BioSynthema or its
sublicensee, in a country following applicable Marketing Authorization of Licensed Product in such country, excluding for use
in a clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="color: Black">&quot;<U>Krenning
Designee</U>&quot; or &quot;Designee&quot; means an individual, corporation, partnership, association, joint-stock company, trust,
which is designated by Krenning pursuant to lawful purposes as the beneficiary of Krenning considerations defined under Article 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5pt"><FONT STYLE="color: Black">&quot;<U>Krenning
License Agreement</U>&quot; means the Agreement dated and signed by Krenning on December 21, 2006 by which Novartis grants Krenning a non-exclusive
license to develop, test, make, have made, use, sell, have sold, offer for sale, distribute, export or import a Licensed Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5pt"><FONT STYLE="color: Black">&quot;<U>Licensed
Product</U>&quot; means any product in the Diagnostic or Therapeutic Field Covered by a Valid Patent Claim, excluding OctreoScan
and OctreoTher, and shall include products, 1) unlabelled in combination with a radioisotope product, or 2) radiolabelled compound,
or 3) an unlabelled compound, sold in a small quantity to be labelled by or for the customer on-site or locally with a generator
isotope for diagnostic purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5pt"><FONT STYLE="color: Black">&quot;<U>Marketing
Authorization</U>&quot; means, with respect to a specific country or region in the Territory, the approval by the appropriate
authority necessary for the Commercialization of a Licensed Product in that country or region. For the sake of clarity, Marketing
Authorization shall not include the reimbursement approval by an appropriate authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5pt"><FONT STYLE="color: Black">&quot;<U>Net
Sales</U>&quot; means, with respect to the Licensed Product (hereinafter collectively referred to as &quot;Product&quot;), the
gross amount invoiced by or on behalf of the relevant Party and its Affiliates, its licensees or sublicensees for the Product
sold to Third Parties other than licensees or sub- licensees in bona fide, arm's-length transactions, less the following customary
deductions, determined in accordance with General Accounting Principles (GAP) as generally and consistently applied by that Party,
to the extent included in the gross invoiced sales price of any Product or otherwise directly paid or incurred by such Party,
its Affiliates or sublicensees with respect to the sale of such Product:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt; text-align: left"></TD><TD STYLE="width: 28pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">normal
                                         and customary trade and quantity discounts actually allowed and properly taken directly
                                         with respect to sales of the Product;</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"></TD><TD><FONT STYLE="color: Black">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">amounts actually repaid or credited by reasons of defects,
rejection recalls, returns, rebates and allowances of goods;</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"></TD><TD><FONT STYLE="color: Black">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">charge-backs and other amounts paid on sale or dispensing
of such Product;</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"></TD><TD><FONT STYLE="color: Black">(iv)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">rebate amounts payable resulting from governmental mandated
rebate programs;</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"></TD><TD><FONT STYLE="color: Black">(v)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">tariffs, duties, excise, sales, value-added and other taxes
(other than taxes based on income);</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"></TD><TD><FONT STYLE="color: Black">(vi)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">customary cash discounts for timely payment; (vii) delayed
ship order credits;</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"></TD><TD><FONT STYLE="color: Black">(viii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">discounts pursuant to indigent patient programs and patient
discount programs and coupon discounts; and</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"></TD><TD><FONT STYLE="color: Black">(ix)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">all freight, postage and insurance included in the invoice
price.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">Sales from a Party
to its Affiliates, its licensees or sublicensee for the Product sold shall be disregarded for purposes of calculating Net Sales.
Any of the items set forth above that would otherwise be deducted from the invoice price in the calculation of Net Sales but which
are separately charged to Third Parties shall not be deducted from the invoice price in the calculation of Net Sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt; text-align: right"><FONT STYLE="color: Black">a)</FONT></TD><TD STYLE="width: 20pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">In the case of any sale or other disposal of the Product
between or among a Party and its Affiliates or sublicensees for resale, Net Sales shall be calculated as above only on the value
charged or invoiced on the first arm's-length sale thereafter to a Third Party;</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt; text-align: right"><FONT STYLE="color: Black">b)</FONT></TD><TD STYLE="width: 20pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">In the case of any sale which is not invoiced or is delivered
before invoice, Net Sales shall be calculated at the time of shipment or when the Product is paid for, if paid for before shipment
or invoice;</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40pt; text-align: right">c) </TD><TD STYLE="width: 20pt"></TD><TD STYLE="text-align: justify">In
the case of any sale or other disposal for value, such as barter or counter-trade, of any Licensed Product, or part thereof, other
than in an arm's-length transaction exclusively for money, Net Sales shall be calculated as above on the value of the non-cash
consideration received or the fair market price (if higher) of the Product in the country of sale or disposal.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5pt"><FONT STYLE="color: Black">In
the event the Product is sold in a finished dosage form containing a Licensed Product in combination with one or more other active
ingredients (a &quot;Combination Product&quot;), the Net Sales of the Product, for the purposes of calculating proposed royalty
payments, shall be determined by multiplying the Net Sales (as defined above in this Article) of the Combination Product by the
fraction, <I>A/(A+B) </I>where A is the weighted (by sales volume) average sale price in a particular country of the Product when
sold separately in finished form and B is the weighted average sale price in that country of the other product(s) sold separately
in finished form. Net Sales for purposes of determining royalty payments shall be agreed by the Parties based on the relative
value contributed by each component, such agreement shall not be unreasonably delayed or withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Party</U>&quot;
means each of Krenning and BioSynthema, and &quot;<U>Parties</U>&quot; means both together.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Patent</U>&quot; means the
patents and patent applications set out in Schedule I, all patents issuing in the future on said patent applications and any divisions,
continuations and continuations-in-part, reexaminations, reissues, additions, extensions, supplementary certificates, and foreign
counterparts thereof. Schedule I will specifically include the list of patents/patent applications corresponding to patent cases
100-7382 and 118-7595.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Royalty
Term</U>&quot; shall be as defined in Section 4.1.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Sublicensee</U>&quot;
means a third party granted certain license rights from BioSynthema for Licensed Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Territory</U>&quot;
means all countries and territories in the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&quot;<U>Therapeutic
Field</U>&quot; means the use of the Licensed Product for therapeutic purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="color: Black">&quot;<U>Third
Party</U>&quot; means a person or entity other than (i) BioSynthema, its Affiliates, distributors or agents, or (ii) Krenning or any
of his designees or agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5pt"><FONT STYLE="color: Black">&quot;<U>Valid
Patent Claim</U>&quot; means on a country-by-country basis a granted claim within the Patent, which has not been held invalid
and/or unenforceable in a decision of a patent office, court or other government agency of competent jurisdiction, unappealable
or unappealed within the time frame allowed for appeal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B><U>ARTICLE 2.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B><U>LICENSE GRANT
BY [*]</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black"><B>2.1 License<FONT STYLE="font-size: 10pt">.</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black">Subject to the
terms and conditions of this Agreement, Krenning grants to BioSynthema all of Krenning's rights and interests to a worldwide, irrevocable,
non-exclusive license, including the right to grant sublicenses, to develop, test, make, have made, use, sell, have sold, offer
for sale, distribute, export or import a Licensed Product from the Effective Date of this Agreement and ending with the Expiration
Date, after having the terms of the Patent extended due to regulatory delay where possible under the applicable law (&quot;BioSynthema
License Rights&quot;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black"><B>2.2 Sublicense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">2.2.1 Krenning shall
have the right to disapprove and block a proposed sublicense by BioSynthema of BioSynthema's License Rights to a third party,
in which event Krenning and BioSynthema shall meet to discuss the proposed sublicense by BioSynthema with the intent to resolve any
issues that may arise for the purpose of BioSynthema executing such sublicense with a third party. Notwithstanding the above,
Krenning has approved BioSyntbema's right to enter into a sublicense agreement with Mallinckrodt Inc., for the license of BioSynthema's
sublicense rights for the licensed product referred to as Lutate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 6%"><FONT STYLE="color: Black">2.2.2</FONT></TD><TD STYLE="text-align: justify; width: 84%"><FONT STYLE="color: Black">In
                                         the event that Krenning is unable to act for the purpose of this provision, for any reason,
                                         including that of incapacity or the death of Krenning, Krenning herein designates that Hendrik
                                         van Rossell, residing in Enkhuizen, the Netherlands, shall act in his place at all times
                                         for the purpose of approving a sublicense of BioSynthema to the license rights granted
                                         to BioSynthema by Krenning herein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">2.2.2
Any sublicensee of BioSynthema shall be obligated to Krenning to the same extent that BioSynthema is obligated to Krenning under the Agreement,
(including without limitation with respect to all restrictions, exceptions, royalty obligations, maintenance and availability
for inspection of books and records, reports, termination</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="color: Black">provisions
and other provisions applicable to a sublicense), and any sublicense shall not relieve BioSynthema of any of its responsibilities
under the Agreement and BioSynthema shall be fully responsible and liable for all acts and omissions of its sublicensees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">2.2.3
BioSynthema shall have the right to negotiate a sublicense to the Agreement, as applicable, with a Third Party without notice
to Krenning, and BioSynthema will in good faith negotiate reasonable and customary terms for such sublicense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B><U>ARTICLE 3.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B><U>SUBLICENSE
&amp; AUDITS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black"><B>3.1 Considerations.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black">In the event that a Third Party agrees
to enter into a sublicense agreement with BioSynthema, the sublicense agreement will include specific provisions on payments to
Krenning, including but not be limited to license and sublicense fees, royalty, Patent costs, and any other payments in kind (the &quot;Proceeds&quot;).
In the event there is a conflict between the terms of the Krenning License Agreement and a sublicense agreement, the terms of the Krenning
License Agreement shall prevail, at no costs to Krenning and no financial compensation to BioSynthema by Krenning related to a conflict
between the terms of the Krenning License Agreement and this Agreement, for general or specific damages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black"><B>3.2 Auditing Rights.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">3.2.1
Upon the written request of Krenning and not more than once in each calendar year, BioSynthema shall permit an independent certified
public accounting firm of nationally recognized standing, selected by Krenning and reasonably acceptable to BioSynthema, at Krenning's expense,
to have access during normal business hours to such records of BioSynthema as may be reasonably necessary to verify the accuracy
of the royalty reports hereunder for any years ending not more than twenty-four (24) months prior to the date of such request.
The accounting firm shall disclose to Krenning only whether the records are correct or not and the specific details concerning any
discrepancies. All other confidential information of the accounting firm, including working papers, shall be shared exclusively
with the legal counsel representing Krenning, and its subcontractors, for the purpose of analysis and verification, on a confidential
basis, such that information provided by the accounting firm shall not be disclosed to Krenning.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">3.2.2
If such accounting firm concludes that additional royalties were owed during such period, BioSynthema shall pay the additional
royalties within thirty (30) days of the date of delivery by Krenning to BioSynthema of such accounting firm's written report so concluding.
The fees charged by such accounting firm shall be paid by</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black">BioSynthema, provided
however, that if the audit discloses that the royalties payable by BioSynthema for the audited period are more than one hundred
and five percent (105%) of the royalties actually paid for such period, then Krenning shall pay the reasonable and direct fees and
expenses charged by such accounting firm. Any overpayment determined pursuant to this provision shall be credited to the next
payment due hereunder from BioSynthema. If no further payments by BioSynthema will be due hereunder then a refund of any such
overpayment will be made within thirty (30) days of the delivery of a detailed written accountants' report to the Parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black"><B>3.3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Underpayment.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">If
at any time during the Term of the Agreement and thereafter, it is determined that BioSynthema or its Exclusive Licensee underreported
sales to Krenning, then any royalty payments related to such under reporting of sales shall be reported and paid to Krenning within sixty
(60) days of BioSynthema or its Exclusive Licensee's first knowledge of such underpaymentwith Interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B><U>ARTICLE 4.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B><U>CONSIDERATION
TO [*]</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black"><B>4.1 &nbsp;&nbsp;Royalty.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">4.1.1
Royalty Rate. As a consideration for the license of all of Krenning's rights under the Krenning License Agreement to BioSynthema, BioSynthema
agrees to pay to Krenning or Krenning Designee a royalty on Net Sales of Licensed Product or, if and where BioSynthema License Rights are
licensed to a Third Party, to cause its Sublicensee to pay such royalty on the Territory annual Net Sales of such Licensed Product
during the- Royalty Term according to the following rate:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 120pt; text-align: right"><FONT STYLE="font-size: 10pt; color: Black">4.1.1.1</FONT>&nbsp;&nbsp;</TD><TD STYLE="width: 0pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; color: Black">annual
Net Sales up to USD fifty million ($ 50,000,000), [*] percent ([*]</FONT><FONT STYLE="color: Black">%)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 120pt; text-align: right"><FONT STYLE="color: Black">4.1.1.2&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 0pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">incremental annual Net Sales from USD fifty million ($50,000,000)
through USD one hundred million ($100,000,000), [*] percent ([*]%)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 120pt; text-align: right"><FONT STYLE="color: Black">4.1.1.3&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 0pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black">incremental annual Net Sales above USD one hundred million
($100,000,000), [*] percent ([*]%)</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt; color: Black">Payments
to Krenning by BioSynthema shall be made in Euros for all Net Sales invoiced in Euros by BioSynthema or its Sublicensee, without currency
conversion, and in US Dollars for all other Net Sales. Such payments </FONT><FONT STYLE="color: Black">will <FONT STYLE="font-size: 10pt">be
non-refundable and will not be subject to any claims by BioSynthema, its Sublicensee, or any Third party, for any reason.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">4.1.2 &nbsp;&nbsp;Royalty Term.
The duration of the royalty obligation shall be determined on a country-by-country basis. Royalties shall be payable quarterly
from the First Commercial Sales of the Licensed Product in a country (i) for the period such Licensed Product's use or sale is
Covered by a Valid Patent in such country, or (ii) for a period of ten (10) years from First Commercial Sales; and if both (i)
and (ii) are applicable, for the longer of either.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">4.1.3
&nbsp;&nbsp;Report. BioSynthema sha11generate a report for Krenning within sixty (60) days of the end of each calendar quarter and BioSynthema
shall make payment in full to Krenning the amount due Krenning for the previous calendar quarter within sixty (60) days of issuing such
report. The report shall set forth by country, (i) the Net Sales of Licensed Product, (ii) the number of units of Licensed Product
sold and the royalties payable hereunder, (iii) the withholding taxes, if any, required by law to be deducted in respect of such
sales, (iv) the date of the First Commercial Sales of the Licensed Product in each country during the reporting period, and (v)
the exchange rates used in determining the amount of US Dollars, for such payments that are to be made in US Dollars. With respect
to sales of the Licensed Product invoiced in Euros, the Net Sales, and royalties payable shall be expressed in Euros. ' With respect
to sales of the Licensed Product invoiced in a currency other than Euros, the Net Sales and amounts due to Krenning hereunder will
be expressed in the US Dollars equivalent calculated on a monthly basis in the currency of the country of sale and converted to
their US Dollar equivalent using the following method:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify"><FONT STYLE="color: Black">The Net Sales in
each country in the Territory at each quarterly period shall be calculated by translating the Net Sales in local currency in each
country in the Territory into those in Euros using the exchange rate mechanism in accordance with General Accounting Practice
(GAP) as generally and consistently applied by U.S. Commercial Pharmaceutical Companies, for such currency calculations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">4.1.4
&nbsp;&nbsp;&nbsp;Interest. Payments due by BioSynthema under the Agreement, when overdue, shall bear interest at a rate per annum equal to LIBOR
(London Interbank Offered Rate) plus one percent (1%) at the time such payment is due, and for the time period until payment is
received by Krenning.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">4.1.5
&nbsp;&nbsp;&nbsp;Confidential Financial Information. Krenning shall treat all financial information subject to review under this Article
4 as confidential and shall cause his accounting firm to retain all such financial information in confidence, subject to Section
9.2.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">4.1.6 &nbsp;&nbsp;&nbsp;Payment
Method. Royalty, License Fee and Interest payments by BioSynthema under the Agreement shall be paid in US Dollars and/or in Euros
as provided for in Section 4.1.2, by bank wire transfer or bank check in immediately available funds to such accounts as Krenning shall
designate before such payment is due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.05pt; color: #31312B"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.05pt; color: #31312B"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">&nbsp;4<FONT STYLE="font-family: Times New Roman, Times, Serif">.1.7
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exchange Control</U>. If at any time legal restrictions prevent the prompt remittance of part or all royalties with respect
to any country where Licensed Product is sold, payment shall be made through such lawful means or methods as BioSynthema shall
reasonably determine after consultation with Krenning.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">4.1.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Royalty Accrual</U>. There shall be no obligation to pay Krenning royalties on a reasonable amount of samples lawfully used in the
Territory and on Licensed Product used (and not sold) during pre-clinical or clinical testing, or for physician preference testing,
teaching or experimental purposes, or for any other similar pre-commercial uses of Licensed Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0"><FONT STYLE="color: Black"><B>4.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designee.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">4.2.1&nbsp;&nbsp;&nbsp;
Krenning shall be entitled to assign his consideration rights during the term of the Agreement to a Designee, upon three months notice
to BioSynthema or its Sublicensee and to cancel such assignment upon a three months prior notice to BioSynthema or its Sublicensee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">4.2.2
&nbsp;&nbsp;&nbsp;BioSynthema's payment to Designee shall relieve BioSynthema of any same payment to Krenning. BioSynthema shall not be liable for any
additional tax or costs that such Third Party beneficiary payment may cause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B><U>ARTICLE 5.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="color: Black"><B><U>PATENTS AND
OWNERSHIP OF INTELLECTUAL PROPERTY</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0"><FONT STYLE="color: Black"><B>5.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent Prosecution and Maintenance.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">5.1.1
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Krenning License, Novartis shall have the first responsibility to draft, file, extend, prosecute (including conducting
opposition proceedings), and maintain (including conducting opposition proceedings) the Patent, and any and all of its substitutions,
extensions, or supplementary protection certificates, reissues, renewals, divisions, patents of addition, or registrations of
any kind, in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">5.1.2
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All costs associated with filing, prosecution, maintenance, and term extension associated with regulatory delay of Patents shall
be borne by Novartis .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">5.1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Cooperation</U>. Krenning will keep BioSynthema informed of any notice from Novartis, of Novartis making any major decision relating
to the maintenance of the Patent, and Krenning shall provide written notification of such change no less than ninety (90) days prior
to any change relating to the maintenance of the Patents in a country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.05pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">5.1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Should Novartis decide to abandon
the Patent in one or several countries Krenning assigns all of his rights to maintain the Patent under the Krenning License to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="color: Black">BioSynthema. Krenning
shall provide written notice to BioSynthema thereof no less than five (5) days from receipt of notice from Novartis of its intent
to abandon the Patent, and eighty (80) days prior to the final date for filing a response or submitting a payment to the relevant
governmental office regarding such Patent after which the Patent would become abandoned. After receiving such notice, BioSynthema
may, but is not obligated to, elect to continue preparation, filing and prosecution or maintenance of the discontinued Patent
at its sole expense. Ownership of any such abandoned Patents by Novartis shall at the request of BioSynthema be fully assigned
by Krenning to BioSynthema. BioSynthema shall promptly prepare and execute such documents and perform such acts as may be reasonably
necessary for assigning such sole ownership to BioSynthema at BioSynthema's sole expense and at no cost to Krenning.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">5.1.5
Upon abandonment by Novartis of the Patents and election by BioSynthema to maintain said Patents Krenning shall provide reasonable
assistance to BioSynthema and cooperate in the defense of the Patents at the reasonable request of BiuSynthema, at BioSynthema's
sole expense. BioSynthema or its Sublicensee shall also provide to Krenning upon abandonment of the Patents that BioSynthema elects
to continue, all relevant documentation of Patents filings including, but not limited to, records pertaining to the preparation,
filing and maintenance of the Patents, at BioSynthema's or its Sublicensee's sole expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0"><FONT STYLE="font-size: 10pt; color: Black">5.</FONT><FONT STYLE="color: Black"><B>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Infringement Claims Against Third Parties</B><FONT STYLE="font-size: 10pt">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">5.2.1
<U>Cooperation</U>. Each Party shall promptly provide written notice to the other Party during the Agreement Term of any known
infringement or suspected infringement of the Patents by a Third Party's commercial making, using, offering for sale, selling,
or importing Licensed Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">5.2.2 Under the
Krenning License, Novartis shall have the first right, but not the obligation, to take, institute and prosecute legal proceedings of
Patent infringements. In the event that Novartis elects not to take, institute and prosecute legal proceedings of Patent infringement
by a Third Party, BioSynthema shall have the right, but Dot the obligation to take such action, without the approval of Krenning. Any
such action taken under this Section 5.2.2 shall be at BicSynthema's or its Sublicensee's sole - costs and benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 12.95pt"><FONT STYLE="color: Black"><B><U>ARTICLE
6.<BR>
 TRADEMARKS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">BioSynthema shall have the sole right
to select a trademark for Licensed Product (&quot;BioSynthema Trademarks)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B><U>ARTICLE 7.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B><U>SUPPLY OF
LICENSED PRODUCT FOR RESEARCH</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black"><B>Erasmu<FONT STYLE="font-family: Times New Roman, Times, Serif">s
Pricing for Licensed Product Used for Research</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">. In the event
that Licensed Product is approved for patient use by Erasmus, BioSynthema agrees, and shall cause its Sublicensees, if any, to
agree to supply Licensed Product to Krenning and to Erasmus for all of Erasmus' Product needs at the best price the Product is sold
in the European Union.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B><U>ARTICLE <FONT STYLE="font-size: 10pt">8.</FONT></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B><U>REPRESENTATIONS,
WARRANTIES AND COVENANTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">8.1
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Representations and Warranties of Both Parties</B>. Each Party warrants and represents to the other Party that it has the full
right and authority to enter into the Agreement and that to the best of its knowledge it is not aware of any reason which would
inhibit its ability to perform the terms and conditions imposed on it by the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">8.2
&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations and Warranties of Krenning</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.05pt"><FONT STYLE="color: Black"><U>No
Material Misstatements</U>. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Krenning has not intentionally failed to disclose any information actually known to it which would be material
to BioSynthema entering into this Agreement, and to the best of his knowledge such information does not contain any untrue statement
of material fact or omit to state a material fact.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;Representations and Warranties
of BioSynthema</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">8.3.1
&nbsp;&nbsp;&nbsp;&nbsp;BioSynthema is duly organized and validly existing under the Laws of Missouri, USA and has fun legal power and authority to
enter into the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">8.3.2
&nbsp;&nbsp;&nbsp;&nbsp;BioSynthema is not subject to any order, decree or injunction by any court of competent jurisdiction which prevents or materially
delays the consummation of the transaction contemplated by the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify"><FONT STYLE="color: Black">8.3.3&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Material Misstatements</U>. BioSynthema (i) has fully disclosed to Krenning; (ii) has not intentionally failed to disclose any
information actually known to it which would be material to Krenning entering into the Agreement, and to the best of its knowledge
such information does not contain any untrue statement of material fact or omit to state a material fact.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 35.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: left"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="color: Black"><B><U>ARTICLE
9. <BR>
CONFIDENTIAL INFORMATION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="color: Black">9.1</FONT></TD><TD STYLE="width: 20pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Treatment of Confidential Information</B>. In carrying
out rights and obligations under the Agreement, the Parties may share proprietary information, but shall not be required to share
proprietary information, which shall include any information in any form, whether disclosed orally, or in writing, of any nature,
including, without&#9;limitation all: writings, reports, trade secrets, discoveries, ideas, inventions, know-how, business plans,
business opportunities, future projects or products, projects or products under consideration, information related to [mances,
costs, prices (&quot;Confidential Information&quot;) with each other. Except as permitted by this Agreement, each Party shall
and shall cause its/his Affiliates and/or licensees/sublicensees to treat Confidential Information received from the other Party
as it treats its own proprietary information. In particular, it shall not disclose, divulge or otherwise communicate such Confidential
Information to Third Parties, or use it for any purpose except pursuant to and in order to carry out its obligations under the
Agreement during the Agreement Term; provided that, each Party (i) may disclose the Confidential Information to such of its directors,
officers,&#9;employees, Affiliates, consultants, subcontractors, licensees, sublicensees, agents to the extent reasonably necessary
to carry out its obligations under the Agreement and so far as disclosure is made to each individual on a need to know basis and
each individual is bound by obligations of confidentiality at least as strict as those contained within the Agreement, and (ii)
hereby agrees to exercise every reasonable precaution to prevent and restrain the unauthorized disclosure or use of Confidential
Information.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="color: Black">9.2</FONT></TD><TD STYLE="width: 20pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="color: Black"><B>Release from Restrictions</B>. The provisions of this
Article 9 shall not apply to any Confidential Information which:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.05pt"><FONT STYLE="color: Black">9.2.1 &nbsp;&nbsp;was known or used by the receiving
Party or its Affiliates prior to its date of disclosure to the receiving Party or its Affiliates by the disclosing Party or its
Affiliates, as evidenced by the prior written records of the receiving Party or its Affiliates; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.05pt"><FONT STYLE="color: Black">9.2.2
&nbsp;&nbsp;either before or after the date of the disclosure to the receiving Party or its Affiliates, is lawfully disclosed to the receiving
party or its Affiliates by a Third Party rightfully in possession of the Confidential Information and not in breach of any obligation
of confidentiality to the disclosing Party; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><FONT STYLE="color: Black">9.2.3
&nbsp;&nbsp;either before or after the date of the disclosure to the receiving Party or its Affiliates, becomes published or generally known
to the public through no fault or omission on the part of the receiving Party or its Affiliates, but such inapplicability applies
only after such information is published or becomes generally known; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><FONT STYLE="color: Black">9.2.4
&nbsp;&nbsp;is independently developed by or on behalf of the receiving Party or its Affiliates without reference to or reliance upon any
Confidential Information of the disclosing Party or its Affiliates; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">9.2.5
is reasonably determined to be required to be disclosed by the receiving Party or its Affiliates to comply with applicable securities
or other laws, to defend or prosecute litigation or to comply with governmental regulations; the receiving Party or its Affiliates
shall provide prior written notice within twenty (20) days of such disclosure to the disclosing Party or its Affiliates and shall
take reasonable and lawful actions to prevent such disclosure and/or minimize the degree of such disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.05pt"><FONT STYLE="color: Black">9.3
<FONT STYLE="font-size: 10pt"><B>Exceptions</B>. </FONT>The restrictions set forth in this Article 9 shall not prevent either
Party from (i) preparing, filing, prosecuting or maintaining a patent application or its resulting patents related to a Licensed
Product in accordance with the terms of the Agreement; (ii) disclosing Confidential Information to governmental agencies to the
extent required or desirable to secure government approval for the development or marketing of a Licensed Product; or (iii) disclosing
all the necessary information to potential Third Party licensees or sublicensees, respectively, provided such Third Party is bound
by confidentiality provisions at least as strict as the ones contained herein. In particular, Krenning expressly authorizes BioSynthema
to disclose the relevant terms of this Agreement to a potential sublicensee of Licensed Product. Such exception to the Confidentiality
provisions does not allow BioSynthema to disclose any of the terms of the Agreement to other third parties without the approval
of Krenning.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #4D4D49"><FONT STYLE="color: Black"><B><U>ARTICLE
10.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B><U>TERM AND REMEDIES
FOR BREACH</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.05pt"><FONT STYLE="color: Black">10.1&nbsp;&nbsp;&nbsp;
<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Agreement Term</U></B>. The Agreement Term shall commence on the Effective Date and end, unless earlier terminated pursuant
to Section 10.2.1 on the Expiration Date under the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.05pt"><FONT STYLE="color: Black">10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B><U>Termination for Breach.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">10.2.1
Either Party shall have the right to terminate the Agreement at any time with immediate effect by giving written notice to the
other in the event that the other Party should willfully breach its obligation under the Agreement and should fail or be unable
to rectify that breach either (i) within ninety (90) days of receipt of written notice specifying the breach, or (ii) within such
additional time as may be reasonably necessary to rectify the breach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">10.2.2
In all other cases of breach, the exclusive remedy to a non-breaching Party for any material breach of the Agreement by the other
Party shall be solely for monetary damages plus interest; no other remedies available by law or otherwise shall apply for a breach
of the Agreement. The non-breaching Party shall have the right to demand monetary damages for alleged breach of the Agreement
by the other Party, at any time with immediate effect, by giving written notice to the other Party in the event that the other
Party should commit an alleged material breach of the terms of the Agreement and should fail or be unable to rectify that breach
either (i) within sixty (60) days of receipt of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0"><FONT STYLE="color: Black">&nbsp;written notice specifying the breach, or <FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)
within such additional time as may be reasonably necessary to rectify the breach. For the sake of clarity, neither Party shall
be entitled to terminate the Agreement for material breach by the other Party, except as provided under 10.2.1.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black"><B>10.3&nbsp;&nbsp;&nbsp;&nbsp;
<U>Termination for Bankruntcy</U></B>. Only if required by applicable law, shall a Party have the right to terminate the Agreement
in the event that the other Party becomes insolvent, makes assignment for the benefit of the creditors, is the subject of proceedings
in voluntary or involuntary bankruptcy instituted on behalf of or against such Party (except for involuntary bankruptcies which
are dismissed within ninety (90) days), or has a receiver or trustee appointed for substantially all of its property. In the event
of the insolvency of a Party, the other Party shall seek only monetary remedies through the applicable courts, and shall not seek
termination of the Agreement. All remedies granted the Party not seeking court administration of its agreements and or operations,
by a court of competent jurisdiction in insolvency and bankruptcy matters, shall be the sale remedies available to the other Party.
In case of termination required by law: (i) due to BioSynthema's insolvency, all the rights shall revert to Krenning, or (ii) due to
Krenning's insolvency, BioSynthema shall have a non-exclusive, perpetual, fully paid-up, royalty-free license under the Remaining Interests,
with the right to sublicense and an exclusive perpetual, fully paid-up, royalty-free license, with the right to sublicense, under
BioSynthema Exclusive Rights. Termination of the Agreement will not release the non-insolvent Party from any obligation to make
any payments to the other Party which were accrued prior to and including the effective date of termination or expiration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black"><B>10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Effect of Termination</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">10.4.1
Upon early termination of this Agreement by BioSynthema due to Krenning's willful and material breach of his obligations under the
Agreement in accordance with Section 10.2.1, BioSynthema shall be entitled to the full proceeds due from any sublicensee or licensee
under a non-exclusive license or sublicense as set forth in Article 3, including the portion of payments that should have normally
been paid to Krenning. In<B> </B>addition, BioSynthema shall have a sale, perpetual, fully paid-up, royalty- free license under the
Remaining Interests, with the right to sublicense, as well as an exclusive perpetual, fully paid-up, royalty-free license, with
the right to sublicense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">10.4.2
Upon early termination by Krenning due to BioSynthema's willful and material breach of its obligations under the Agreement in accordance
with Section 10.2.1, all the rights granted by Krenning hereunder shall revert to Krenning. In addition, Krenning shall be entitled to the full
Proceeds due from any of sublicensee or licensee as set forth in Article 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><FONT STYLE="color: Black"><B>10.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Survival.</U> </B>Any other provision and any definitions used in such Sections or Article which, by its terms, is understood
to survive the termination or expiration of the Agreement shall survive the expiration or termination<FONT STYLE="font-size: 10pt">
</FONT>of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 20.15pt"><FONT STYLE="color: Black"><B><U>ARTICLE
11.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 20.15pt"><FONT STYLE="color: Black"><B><U>INDEMNIFICATION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black"><B>11.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Indemnification by the Parties</U>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">11.1.1
&nbsp;&nbsp;Krenning agrees to indemnify and hold BioSynthema and its directors, officers, employees and agents (the &quot;BioSynthema Indemnified
Parties&quot;) harmless from and against any claims, losses, costs, damages, fees or expenses arising out of or otherwise relating
to (i) the gross negligence or willful misconduct of Krenning or (ii) a breach by Krenning of any of his representations, warranties, covenants
or agreements (&quot;BioSynthema Losses&quot;). The foregoing indemnification shall not apply to BioSynthema Losses to the extent
that they are caused by the gross negligence or willful misconduct of BioSynthema.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">11.1.2
&nbsp;&nbsp;BioSynthema agrees to indemnify and hold harmless Krenning from and against any claims, losses, costs, damages, fees and expenses arising
out of or otherwise relating to (i) the development, manufacture, if applicable, labelling, use, offer for sale, sale or other
disposition of Licensed Product, (ii) the gross negligence or willful misconduct of BioSynthema or its sublicensee(s), or (iii)
a breach by BioSynthema of any of its representations, warranties, covenants or agreements (&quot;Krenning Losses&quot;). The foregoing
indemnification shall not apply to Krenning Losses to the extent that they are caused by the gross negligence or willful misconduct
of Krenning.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 15.85pt"><FONT STYLE="color: Black"><B><U>ARTICLE
12.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 15.85pt"><FONT STYLE="color: Black"><B><U>MISCELLANEOUS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.5pt; text-align: justify"><FONT STYLE="color: Black"><B>12.1&nbsp;&nbsp;&nbsp;
Publicity. </B>Neither party shall originate any publicity, news release or other public announcement, written or oral,
relating to the Agreement, including its terms, without the prior - approval of the other Party. Any such approval shall not
be unreasonably withheld or delayed. Each Party shall to the extent consistent with applicable laws and regulations limit the
disclosure of the financial terms set forth in this Agreement (such as by requesting confidential treatment of such terns in
documents required to be filed with the U.S. Securities and Exchange Commission).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><FONT STYLE="color: Black"><B>12.2
&nbsp;&nbsp;&nbsp;Force Majeure. </B>Neither Party to the Agreement shall be responsible to the other Party for non performance or delay in performance
of the terms or conditions of the Agreement due to acts of governments, war, riots, strikes, accidents in transportation, or other
causes beyond the reasonable control of such Party, but such force majeure shall toll any and all obligations and time periods
for so long as such force majeure continues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.75pt"><FONT STYLE="color: Black"><B>12.3
&nbsp;&nbsp;&nbsp;Governing Law. </B>The Agreement shall be governed by and interpreted in accordance with the laws of the Netherlands without giving
effect to principles of conflicts of law. Any dispute which cannot be solved amicably shall be submitted to the exclusive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">jurisdiction of
the courts of Amsterdam, the Netherlands, should Krenning be the defendant, and of the courts of the City of St. Louis, Missouri, should
BioSynthema be the defendant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 29.75pt"><FONT STYLE="font-size: 10pt; color: Black"><B>12.4&nbsp;&nbsp;
Waiver. </B></FONT><FONT STYLE="color: Black">The waiver by a Party of a breach or a default of any provision of the Agreement
by the other Party shall not be construed as a waiver of any succeeding breach of the same or any other provision, nor shall any
delay or omission on the part of a Party to exercise or avail itself of any right, power or privilege that it has or may have
hereunder operate as a waiver of any right, power or privilege by such Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.25pt"><FONT STYLE="font-size: 10pt; color: Black"><B>12.5
&nbsp;&nbsp;Notices. </B></FONT><FONT STYLE="color: Black">Any notice or other communication in connection with the Agreement must be in writing
and may be given by any of the following methods: (i) personal delivery against a signed receipt; (ii) registered or certified
mail, postage prepaid, return receipt requested; (iii) by overnight delivery service which obtains a signed receipt; or (iv) by
facsimile transmission with confirmation of delivery. Notice shall be effective when delivered to the addressee at the address
listed below or such other address as the addressee shall have specified in a written notice actually received by the addresser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.25pt"><FONT STYLE="color: Black">If to Krenning:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; text-align: justify"><FONT STYLE="color: Black">Professor Dr. Eric P. Krenning<BR>
Hoflaan 71<BR>
3062 IC Rotterdam<BR>
The Netherlands</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="color: Black">If to BioSynthema:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"><FONT STYLE="color: Black">Jack L. <FONT STYLE="font-size: 10pt">Erion</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"><FONT STYLE="color: Black">President</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"><FONT STYLE="color: Black">4041 Forest Park Blvd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"><FONT STYLE="color: Black">St. Louis, Missouri 63108</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"><FONT STYLE="color: Black">USA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"><FONT STYLE="color: Black">With a copy to BioSynthema General
Counsel:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"><FONT STYLE="color: Black">Mary A. Palank</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"><FONT STYLE="font-size: 10pt; color: Black">Palank </FONT><FONT STYLE="color: Black">&amp;
<FONT STYLE="font-size: 10pt">Associates LLC</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"><FONT STYLE="color: Black">1034 S. Brentwood Blvd., Suite
1630</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"><FONT STYLE="color: Black">St. Louis, Missouri 63117</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"><FONT STYLE="color: Black">USA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><FONT STYLE="color: Black"><B>12.6
&nbsp;&nbsp;&nbsp;Payments. </B>All payments to be made by either Party to the other Party shall be made to the bank account of the receiving Party
as directed in writing by the receiving Party at the time payment is to be made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 68.5pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.05pt"><FONT STYLE="color: Black"><B>12.7
&nbsp;&nbsp;&nbsp;No Agency. </B>Nothing herein shall be deemed to constitute an agency, joint venture, amalgamation,
partnership or other similar relationship between BioSynthema and Krenning. Each Party shall be an independent contractor, not an
employee or partner of the other Party. Each Party shall be responsible for the conduct of activities and for any liabilities
resulting therefrom. Neither Party shall be responsible for the acts or omissions of the other Party, nor will either Party
have the authority to speak for, represent or obligate the other Party in any way without prior written authority from the
other Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35.5pt; text-align: justify"><FONT STYLE="color: Black"><B>12.8 &nbsp;&nbsp;&nbsp;Entire
Agreement. </B>The Agreement and Schedules hereto (which Schedules are deemed to be a part of the Agreement for all purposes)
contain the full understanding of the- Parties with respect to the subject matter hereof and supersede, cancel and annul any prior
written or oral understandings and agreements relating thereto. No waiver, alteration or modification of any of the provisions
hereof shall be binding unless made in writing and signed by the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.05pt"><FONT STYLE="color: Black"><B>12.9
&nbsp;&nbsp;&nbsp;Headings. </B>The headings contained in the Agreement are for convenience of reference only and shall not be considered in construing
the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><FONT STYLE="color: Black"><B>12.10
&nbsp;Severability. </B>In the event that any provision of the Agreement is held by a court of competent jurisdiction to be unenforceable
because it is invalid or in conflict with any law of any relevant jurisdiction, the validity of the remaining provisions shall
not be affected, and the Parties shall negotiate a substitute provision that, to the extent possible, accomplishes the original
business purpose. During the period of such negotiation, and thereafter if no substituted provision is agreed upon, any such provision
which is enforceable in part but not in whole shall</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">be enforced to the maximum extent permitted
by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><FONT STYLE="color: Black"><B>12.11
&nbsp;&nbsp;&nbsp;Assignment. </B>Neither the Agreement nor any of the rights or obligations hereunder may be assigned by either Party without the
prior written consent of the other Party, except to an Affiliate of the assigning Party and such assignment shall only remain
effective as long as such Affiliate remains an Affiliate of the assigning Party or to any other Third Party who acquires all or
substantially all of the business to which the Agreement relates of the assigning Party by merger, sale of assets or otherwise,
so long as such Affiliate or Third Party agrees in writing to be bound by the terms of the Agreement. In all cases the assigning
Party shall provide the other Party with prompt notice of any such assignment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><FONT STYLE="color: Black"><B>12.12
&nbsp;&nbsp;&nbsp;Successors and Assigns. </B>Except as otherwise provided herein, the Agreement shall be binding upon and inure to the benefit
of the Parties hereto and their successors and permitted assigns under Section 12.11.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><FONT STYLE="color: Black"><B>12.13
&nbsp;&nbsp;&nbsp;Counterparts. </B>The Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all
of such together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.05pt"><FONT STYLE="color: Black">IN
WITNESS WHEREOF, the Parties hereto have caused the Agreement to be executed in their names by their properly and duly authorized
officers or representatives as of the dates below written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 70%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B>Professor Dr. Eric P. Krenning</B></FONT></td>
    <TD STYLE="width: 30%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B>BIOSYNTHEMA
    Inc.</B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">Date: June
    12<SUP>th</SUP> 2007</FONT></td>
    <td style="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">Date:
    June 12<SUP>th</SUP> 2007</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">/s/ Hendrik van Rossem</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">By: </FONT></td>
    <TD STYLE="width: 45%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Hendrik van Rossem</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Title: </FONT></td>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Chairman</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">Certain confidential information has
been omitted from this document, as indicated by the notation &ldquo;[*]&rdquo;. The omitted information has been filed on a confidential
basis with the Securities and Exchange Commission pursuant to a request for confidential treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="color: Black"><B>SCHEDULE 1 &mdash;
</B>1. <B>Patent </B>(Case 100-7382)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 36%; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: Black"><B>Country</B></FONT></td>
    <TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt; color: Black"><B>&nbsp;</B></FONT></td>
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: Black"><B>Grant
    Date</B></FONT></td>
    <TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt; color: Black"><B>&nbsp;</B></FONT></td>
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: Black"><B>Patent
    n&deg;</B></FONT></td>
    <TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt; color: Black"><B>&nbsp;</B></FONT></td>
    <TD STYLE="width: 18%; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: Black"><B>Exp.
    Date</B></FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Australia</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">04.06.93</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">633859</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">04.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Austria</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">09.12.97</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">403476</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">30.11.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Belgium</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">20.11.90</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">1002296</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">05.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Canada</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">22.02.00</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">2004532</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">04.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Cyprus</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">01.12.95</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">1893</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">01.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Denmark</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">30.08.04</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">175338</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">05.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Finland</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">30.09.98</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">101967</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">11.07.14</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Finland</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">31.12.98</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">102540</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">04.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">France</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">21.04.95</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">8915993</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">04.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Germany</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">20.04.06</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">3991505</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">30.11.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Great Britain</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">20.01.93</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">2225579</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">01.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Greece</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">26.11.96</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">1002475</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">05.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Hong Kong</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">21.12.95</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">1899/95</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">01.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Hungary</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">20.09.95</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">211468</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">01.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Ireland</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">05.12.94</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">62091</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">04.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Israel</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">25.09.94</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">92534</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">04.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Italy</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">19.10.93</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">1239285</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">05.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Japan</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">10.06.05</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">3686503</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">04.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Japan</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">05.12.97</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">2726320</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">04.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Korea South</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">22.07.98</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">156541</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">22.07.13</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Luxemburg</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">18.09.91</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">87633</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">05.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Malaysia</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">31.03.95</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">106120</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">31.03.10</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Netherland</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">03.04.03</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">194828</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">04.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">New Zealand</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">20.01.94</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">231623</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">04.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Nigeria</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">13.04.93</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">10732</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">05.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Pakistan</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">21.03.92</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">132014</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">05.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Philippines</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">07.05.96</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">29649</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">07.05.13</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Poland</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">28.09.93</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">163432</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">04.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Portugal</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">20.10.95</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">92487</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">20.10.10</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Saudi Arabia*</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">01.01.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Singapore</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">15.04.97</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">38709</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">01.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">South Africa</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">28.08.91</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">89/9285</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">05.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Spain</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">22.11.91</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">2023533</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">05.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Sweden</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">09.11.98</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">8904087-7</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">04.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Switzerland</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">30.08.91</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">678329-6</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">30.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Tanganyida</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">30.09.97</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">2533</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">01.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">Trinidad+Tabago</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">14.11.95</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">78/95</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">01.12.09</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">USA</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">19.05.98</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">5753627</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">06.06.15</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: Black"><B>Country</B></FONT></td>
    <TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt; color: Black"><B>&nbsp;</B></FONT></td>
    <TD STYLE="width: 28%; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: Black"><B>Grant
    Date</B></FONT></td>
    <TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt; color: Black"><B>&nbsp;</B></FONT></td>
    <TD STYLE="width: 22%; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: Black"><B>Patent
    n&deg;</B></FONT></td>
    <TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt; color: Black"><B>&nbsp;</B></FONT></td>
    <TD STYLE="width: 24%; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: Black"><B>Exp.
    Date</B></FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">USA</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">07.07.98</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">5776894</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">07.07.15</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">*Saudi Arabia: patent application still
pending, filing number 95160495</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="color: Black"><B>SCHEDULE Ia &mdash; Additional Patent
</B>(Case 100-7774)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 33%; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: Black"><B>Country</B></FONT></td>
    <TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt; color: Black"><B>&nbsp;</B></FONT></td>
    <TD STYLE="width: 22%; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: Black"><B>Grant
    Date</B></FONT></td>
    <TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt; color: Black"><B>&nbsp;</B></FONT></td>
    <TD STYLE="width: 19%; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: Black"><B>Patent
    n&deg;</B></FONT></td>
    <TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt; color: Black"><B>&nbsp;</B></FONT></td>
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: Black"><B>Exp.
    Date</B></FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">Belgium</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">09.08.00</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">515313</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">20.05.12</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">Canada</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">07.01.03</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">2069154</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">21.05.12</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">France</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">09.08.00</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">515313</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">20.05.12</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">Germany</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">09.08.00</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">515313</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">20.05.12</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">Great Britain</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">09.08.00</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">515313</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">20.05.12</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">Italy</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">09.08.00</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">515313</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">20.05.12</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">Japan</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">14.02.03</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">3397338</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">22.05.12</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">Netherlands</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">09.08.00</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">515313</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">20.05.12</FONT></td></tr>
<tr style="vertical-align: top">
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">Switzerland</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">09.08.00</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">515313</FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black">20.05.12</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
